EDIT Earnings

EDIT reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 7.54M against an estimate of 4.95M, resulting in a 52.55% surprise. The EPS was 0, surpassing the expected -0.38 by 0%. The stock experienced a 2.02% price change on the earnings day and a 2.83% change over the next five days, reflecting market reactions to the results.

Following EDIT's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by 2.02% on the day of the release. Over the subsequent five days, it saw a 2.83% change. Historically, EDIT's stock price tends to shift by an average of 10.66% in the 10 days leading up to earnings and -1.2% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate EDIT's annual revenue to reach 8.45M, while the EPS is projected at -0.21. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EDIT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EDIT's stock price typically moves by 10.66% in the 10 days before its earnings and -1.2% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.21 and revenue of 8.45M.

The earnings call summary and Q&A reveal mixed signals. While there are positive aspects like the collaboration with Bristol-Myers Squibb and ongoing development in the reni-cel program, there are concerns about declining revenue and increased R&D expenses. The management's vague responses on timelines and specifics add uncertainty. The strong cash position is a positive, but the market may react neutrally due to the lack of immediate catalysts and clear guidance. Without the market cap, a neutral rating is prudent.